Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$25.15 USD
+0.49 (1.99%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.96 | -127.39 | -125.55 | -66.15 | -77.19 |
Depreciation/Amortization & Depletion | -1.26 | 2.82 | 4.61 | 2.76 | 1.93 |
Net Change from Assets/Liabilities | -19.51 | -7.77 | -3.31 | -19.02 | 26.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 29.49 | 24.20 | 16.40 | 9.92 | 7.59 |
Net Cash From Operating Activities | -70.24 | -108.14 | -107.87 | -72.48 | -41.53 |
Property & Equipment | -0.61 | -0.80 | -1.10 | -0.47 | -0.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -38.65 | 92.26 | -14.76 | -90.49 | -52.74 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -39.26 | 91.47 | -15.86 | -90.97 | -53.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 171.25 | 19.00 | 130.11 | 258.16 | 36.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -10.52 | 9.77 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.77 | -0.16 | -0.19 | -0.01 | 0.00 |
Net Cash from Financing Activities | 170.48 | 18.84 | 129.92 | 247.63 | 46.04 |
Effect of Exchange Rate Changes | 0.00 | -0.09 | -0.13 | 0.18 | -0.03 |
Net Change In Cash & Equivalents | 60.98 | 2.08 | 6.07 | 84.35 | -49.23 |
Cash at Beginning of Period | 125.97 | 123.89 | 117.82 | 33.47 | 82.69 |
Cash at End of Period | 186.95 | 125.97 | 123.89 | 117.82 | 33.47 |
Diluted Net EPS | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -78.96 | -106.29 | -72.19 | -33.73 |
Depreciation/Amortization & Depletion | NA | -1.26 | -0.74 | -0.56 | -0.42 |
Net Change from Assets/Liabilities | NA | -19.51 | -3.05 | -3.96 | -7.98 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 29.49 | 22.89 | 16.12 | 7.78 |
Net Cash From Operating Activities | NA | -70.24 | -87.20 | -60.59 | -34.35 |
Property & Equipment | NA | -0.61 | -0.59 | -0.19 | -0.01 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -38.65 | 22.62 | 35.77 | 9.84 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -39.26 | 22.03 | 35.59 | 9.83 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 171.25 | 170.72 | 135.40 | 26.56 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.77 | -0.77 | -0.77 | -0.10 |
Net Cash from Financing Activities | NA | 170.48 | 169.95 | 134.64 | 26.46 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 60.98 | 104.78 | 109.64 | 1.94 |
Cash at Beginning of Period | NA | 125.97 | 125.97 | 125.97 | 125.97 |
Cash at End of Period | NA | 186.95 | 230.75 | 235.61 | 127.91 |
Diluted Net EPS | NA | 0.54 | -0.58 | -0.68 | -0.67 |